Avelumab Fails to Extend PFS in Ovarian Cancer

January 2, 2019 5:00 pm

A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS.

The JAVELIN Ovarian 100 study has been terminated based on the finding, reported as part … Read more

Ovarian Cancer ‘Breakthrough’ Drug Prevents Disease Returning for Years

October 22, 2018 4:35 pm

By 

A new ovarian cancer treatment dramatically reduces the chances of the disease returning, a study has shown.

Doctors have hailed the results of a “breakthrough” trial which they say opens the possibility that many more women suffering … Read more

Early Clinical Trials Showing Promise for New Kind of Cancer Vaccine

September 30, 2018 3:14 pm

By Rich Haridy

Promising early results are in from a phase 1 clinical trial into the safety and efficacy of a new cancer vaccine. The new treatment is designed to stimulate the immune system into attacking certain cancers known to … Read more

CTLA4 Targeted Therapy Plus PD-1 Targeted Therapy Could Benefit Women With Ovarian Cancer

September 19, 2018 12:22 am

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more

Drug Combination Gives ‘Exciting’ Results in Ovarian and Lung Cancer in Early Trial

August 24, 2018 1:58 am

Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.

The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more

Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer

August 16, 2018 12:57 am
BY Kristie L. Kahl
The combination use of Tumor Treating Fields (TTFields) and paclitaxel more than doubled progression-free survival (PFS) in patients with recurrent, platinum-resistant ovarian cancer compared with those who received weekly paclitaxel, according to results from the phase … Read more

Quality of Life Maintained With Niraparib for Ovarian Cancer

August 1, 2018 9:19 pm

by Madeline Marr

The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.

An international team of researchers led … Read more

ASCO 2018: Dendritic Cell Vaccine

June 20, 2018 5:46 pm

Dendritic cell vaccine improved progression-free survival when administered sequentially after chemotherapy. The vaccine provides a promising maintenance treatment option to delay progression of epithelial ovarian carcinoma.

This outcome of an interim analysis of a phase II, open-label, randomized, multicenter trial … Read more

Olaparib Plus Vistusertib Promising in Early Trial

June 8, 2018 9:48 pm

The combination of the PARP inhibitor olaparib with an mTORC1/2 inhibitor known as vistusertib was tolerable and had promising activity across endometrial, ovarian, and triple-negative breast cancers, according to a phase I trial. Results of the trial (abstract 5504Read more

PFS Rises in Ovarian Cancer with Repeat Bevacizumab

June 8, 2018 9:47 pm

Women with advanced ovarian cancer previously treated with bevacizumab (Avastin) had a 3-month improvement in progression-free survival (PFS) when they received second-line therapy that included bevacizumab, European investigators reported.

Median PFS increased from 8.8 months with platinum-based chemotherapy to 11.8 … Read more

Pembrolizumab Monotherapy Shows Activity in Advanced Recurrent OC

June 7, 2018 9:52 pm

Pembrolizumab monotherapy is associated with antitumor activity in patients with advanced recurrent ovarian cancer, interim results from the phase 2 KEYNOTE-100 study suggest.

Notably, objective response rates among study subjects increased in tandem with increased programmed death-ligand 1 (PD-L1) expression, … Read more

Non-Chemo Combo Active in Ovarian Cancer

June 6, 2018 7:00 pm

The combination of two targeted agents – the PARP inhibitor niraparib (Zejula) plus the checkpoint inhibitor pembrolizumab (Keytruda) — appears to elicit a durable response among women with heavily pretreated, refractory ovarian cancer, researchers reported here.

About 25% of women … Read more